Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache

June 25, 2018

INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster headache, at the American Headache Society (AHS) annual meeting taking place June 28-July 1 in San Francisco.

Lilly will present late-breaking Phase 3 data for galcanezumab from the largest controlled, preventive trial conducted in episodic cluster headache to date, as well as a late-breaking post-hoc analysis from three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) evaluating galcanezumab for the prevention of migraine in patients who previously failed treatment with Botox® (onabotulinumtoxinA). Lilly will also highlight analyses evaluating the onset and persistence of effect of galcanezumab for the prevention of migraine. Additionally, Phase 3 data evaluating lasmiditan for the acute treatment of migraine will be featured as a platform presentation.

Galcanezumab is a once-monthly, self-administered calcitonin gene-related peptide (CGRP) antibody currently under review by the U.S. Food and Drug Administration (FDA) for the prevention of migraine in adults with a decision expected by the end of September 2018.

Lasmiditan is an investigational, oral, first-in-class molecule that could represent the first significant innovation for the acute treatment of migraine in more than two decades.

Galcanezumab and lasmiditan represent two of three investigational, non-opioid treatments in development as part of Lilly's overall pain portfolio. The portfolio also includes tanezumab, developed in partnership with Pfizer, for the treatment of osteoarthritis pain, chronic low back pain and cancer pain.

"People with migraine and cluster headache can miss out on significant moments in their lives—birthdays, anniversaries, business meetings—and there remains an unmet need for treatment options that can help patients achieve significant reductions in the overall frequency of migraine attacks and cluster headache attacks," said Robert Conley, M.D., Distinguished Lilly Scholar and Lilly global development leader for migraine therapeutics. "The data presented at this year's meeting underscore Lilly's 50-year commitment to address the ongoing challenges in neurology, primary headache disorders and chronic and recurrent pain."

Studies, as well as the dates and times of the data sessions, are highlighted below.

Galcanezumab Data

PLATFORM PRESENTATIONS

Friday, June 29, 2018 – 8:40 – 8:50 a.m. PT

• IOR05: Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Post-Hoc Analyses of Two Phase 3 Studies
  ○ Presenter: Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly and Company, Indianapolis, IN

Saturday, June 30, 2018 – 9:20 – 9:30 a.m. PT and 10:10 – 10:20 a.m. PT

• IOR09: Assessment of Pharmacokinetics, Target Engagement and Immunogenicity in Patients with Migraine Administered Galcanezumab, an Anti-CGRP Antibody
  ○ Presenter: William Kielbasa, research advisor, Eli Lilly and Company, Indianapolis, IN

• IOR03LB: Study CGAL: A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase
  ○ Presenter: Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly and Company, Indianapolis, IN

POSTER PRESENTATIONS

Friday, June 29, 2018 – 1:15 – 2:15 p.m. PT

• PF78: Health Care Resource Utilization and Lost Productivity Time Due to Migraine in the US Population: An Analysis of the Adelphi Disease Specific Programme 2017 Database
  ○ Presenter: Paula Morrow, senior clinical research scientist, Eli Lilly and Company, Indianapolis, IN
• PF80: Evaluation of the Impact of Migraine on Patient Centered Function and Health Related Quality of Life in the U.S. Population Using the Adelphi Disease Specific Programme 2017 Database
  ○ Presenter: Paula Morrow, senior clinical research scientist, Eli Lilly and Company, Indianapolis, IN

• PF84: GPORWE: Psychometric Validation of the MSQv2.1 ePRO for Use in Patients with Episodic and Chronic Migraine
  ○ Presenter: Janet Ford, Ph.D., M.P.H., consultant scientist, Global Patient Outcomes and Real World Evidence, Bio-Medicines, Eli Lilly and Company, Indianapolis, IN

• PF90: Characteristics of Patients with Episodic and Chronic Migraine Based on Monthly Headache Days Reported in a Real-World Electronic Medical Records Database
  ○ Presenter: Shonda A. Foster, PharmD, M.S., RPh, research advisor, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN

Saturday, June 30, 2018 – 1:00 p.m. PT

• PS37: Changes in Patient Functioning and Disability: Results from Two Ph 3 Clinical Trials Evaluating Galcanezumab for Episodic Migraine Prevention (EVOLVE-1 and EVOLVE-2)
  ○ Presenter: Janet Ford, Ph.D., M.P.H., research scientist, Global Patient Outcomes and Real World Evidence, Bio-Medicines, Eli Lilly and Company, Indianapolis, IN

• PS39: Analysis of Initial Non-Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2 and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
  ○ Presenter: Russell Nichols, clinical research scientist, Eli Lilly and Company, Indianapolis, IN

• PS46: Persistence of Effect of Galcanezumab in Patients with Episodic or Chronic Migraine: Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2 and REGAIN Studies
  ○ Presenter: Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly and Company, Indianapolis, IN

• PS48: Patient-Reported Experience with Self-Injection of a Prefilled Syringe vs. Autoinjector in an Open-Label, Long-Term Study of Galcanezumab in Patients with Migraine
  ○ Presenter: Virginia Stauffer, PharmD, senior research advisor, clinical, Eli Lilly and Company, Indianapolis, IN

• PS26: Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of Phase 3 Placebo-Controlled Trials of Patients with Episodic and Chronic Migraine Treated with Galcanezumab
  ○ Presenter: Dustin Ruff, research advisor, Eli Lilly and Company, Indianapolis, IN

• PS29: Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies
  ○ Presenter: Eric Pearlman, M.D., medical fellow, Eli Lilly and Company, Indianapolis, IN

• PS106LB: Positive Response to Galcanezumab Following Treatment Failure with OnabotulinumtoxinA in Patients with Migraine
  ○ Presenter: Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly and Company, Indianapolis, IN

Lasmiditan Data

PLATFORM PRESENTATIONS

Friday, June 29, 2018 – 11:30 a.m. – 1 p.m. PT

• OR03: Lasmiditan Inhibits CGRP Release in the Mouse Trigeminovascular System
  ○ Presenter: Antoinette Maassen van den Brink, associate professor, Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

Saturday, June 30, 2018 – 8:10 a.m. – 8:20 a.m. PT

• IOR02: Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan Compared to Placebo for Acute Treatment of Migraine
  ○ Presenter: Sheena Aurora, M.D., medical fellow and global launch leader, galcanezumab, Eli Lilly and Company, Indianapolis, IN

POSTER PRESENTATIONS

Saturday, June 30, 2018 – 1:00 p.m. – 2:15 p.m. PT

• PS38: Characterization of Dizziness Treatment-Emergent Adverse Events after Lasmiditan: Findings of the SAMURAI and SPARTAN Phase 3 Acute Migraine Treatment Trials
  ○ Presenter: Stewart Tepper, M.D., professor of neurology, Geisel School of Medicine, Dartmouth College, Hanover, NH
About Migraine

Migraine is a neurological disease characterized by recurrent episodes of severe headache accompanied by other symptoms including nausea, vomiting, sensitivity to light and sound, and changes in vision.\cite{1,2} More than 36 million Americans have migraine, with three times more women affected by migraine compared to men.\cite{3} According to the Medical Expenditures Panel Survey, total annual healthcare costs associated with migraine are estimated to be as high as $56 billion annually in the United States, yet it remains under-recognized and under-treated.\cite{4}

About Cluster Headache

Cluster headache is a disabling headache disorder composed of recurrent "attacks" of intense headaches on one side of the head, frequently associated with pain behind or around one eye, restlessness and agitation.\cite{5,6} Cluster headache attacks typically last between 15 to 180 minutes, occurring near daily to multiple times daily during a cluster period.\cite{6} It is estimated that 85 to 90 percent of cluster headache cases are classified as "episodic" with attacks occurring in periods that last from seven days to one year, separated by pain-free remission periods of three months or longer.\cite{5} The remaining 10 to 15 percent are classified as "chronic" with attacks occurring for more than one year without a remission period, or with remission lasting less than one month.\cite{6}

About Lilly's Commitment to Headache Disorders

For over 25 years, Lilly has been committed to helping people suffering from headache disorders, investigating more than a dozen different compounds for the treatment of migraine, cluster headache and other disabling headache disorders. These research programs have accelerated the understanding of these diseases and furthered the advancement of Lilly's comprehensive late-stage development programs studying galcanezumab for prevention of migraine and cluster headache, and lasmiditan for the acute treatment of migraine. Our goal is to make life better for people with headache disorders by offering comprehensive solutions to prevent or stop these disabling diseases. The combined clinical, academic and professional experience of our experts helps us to build our research portfolio, identify challenges for healthcare providers and pinpoint the needs of patients living with migraine and cluster headache.

About Galcanezumab

Galcanezumab is a monoclonal antibody specifically designed to bind to and inhibit the activity of calcitonin gene-related peptide (CGRP), which is believed to play a role in migraine and cluster headache. Galcanezumab is an investigational once-monthly, self-administered injection under evaluation for the prevention of migraine and cluster headache.

About Lasmiditan

Lasmiditan is an investigational, first-in-class molecule under evaluation for the acute treatment of migraine. Lasmiditan selectively targets 5-HT\textsubscript{1F} receptors expressed in the trigeminal pathway, and has been designed for the acute treatment of migraine without the vasoconstrictor activity associated with some migraine therapies. In March 2017, Lilly completed the acquisition of CoLucid Pharmaceuticals, including lasmiditan, which was originally discovered at Lilly.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about galcanezumab as a potential treatment for patients with migraine and cluster headache; lasmiditan as a potential treatment for patients with migraine; and tanezumab as a potential treatment for patients with osteoarthritis pain, chronic low back pain, and cancer pain; and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that galcanezumab or lasmiditan will achieve their primary study endpoints or receive regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

* Botox® is a registered trademark owned by Allergan, Inc.


Refer to: Jen Dial; dial_jennifer_kay@lilly.com; 317-220-1172 (Lilly Bio-Medicines)

Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (Investor Relations)


SOURCE Eli Lilly and Company